Cough News and Research

RSS

OSI Pharmaceuticals announces European Commission's approval of Tarceva for NSCLC

OSI Pharmaceuticals, Inc. announced today that its international partner for Tarceva® (erlotinib), Roche, received approval from the European Commission for Tarceva as a monotherapy maintenance treatment in patients with advanced non-small cell lung cancer (NSCLC) whose disease remains largely unchanged (stable disease) after platinum-based initial chemotherapy.

29 Apr 2010

More taxes and drab packages for cigarettes to deter the young from smoking

From 1st July 2012 companies making cigarettes will be allowed only to have a brand name and a graphic health warning on their cigarette packs. There has been a huge debate over this issue. Trade experts believe that this move could mean that the Federal Government may have to cough up more than $3 billion a year to cigarette companies. Tim Wilson from the Institute of Public Affairs also believes that this would cost taxpayers $3.4 billion a year in compensation to tobacco companies. However Australia will be the first country to introduce such a measure.

28 Apr 2010

Medication-free home ventilation system designed to remove allergens

According to a recent report by USA Today, due to 2010's unusually cold winter temperatures, allergy sufferers are now poised to experience the worst pollen season in years, with pollen counts skyrocketing and sufferers hiding indoors to avoid exposure. Yet as allergens creep indoors, sufferers continue to cough, sneeze and seek relief. With the introduction of EZ Breathe, a new innovative home ventilation system designed to remove allergens and reduce indoor concentrations of pollen, allergy sufferers now have a medication-free solution.

27 Apr 2010

OSI Pharmaceuticals completes enrollment in Phase III clinical trial of Tarceva

OSI Pharmaceuticals, Inc. announced today that it has completed enrollment in the RADIANT study, a Phase III clinical trial testing Tarceva (erlotinib) as an adjuvant therapy in patients with Stage IB-IIIA non-small cell lung cancer who have undergone surgery and have EGFR-positive tumors.

26 Apr 2010

Children need to be immunized against 14 vaccine-preventable diseases: Secretary of Health

Pennsylvania parents are strongly urged to protect their children by making certain they are fully immunized against preventable diseases, Secretary of Health Everette James said today to mark the start of National Infant Immunization Week, April 24-May 1.

24 Apr 2010

Genentech submits sBLA for Herceptin plus chemotherapy for advanced HER2-positive stomach cancer

Genentech, Inc., a wholly owned member of the Roche Group, announced today that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Herceptin® (trastuzumab) plus chemotherapy in people with advanced, HER2-positive adenocarcinoma of the stomach, including gastroesophageal junction cancer.

23 Apr 2010

Genentech's Tarceva receives FDA approval as maintenance therapy for advanced NSCLC

Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration approved the daily pill Tarceva® (erlotinib) as a maintenance treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.

17 Apr 2010

Results of study comparing REMICADE to azathioprine for Crohn's disease published

Findings published today in The New England Journal of Medicine from a first-of-its-kind comparator trial evaluating the anti-tumor necrosis factor (TNF)-alpha biologic treatment REMICADE (infliximab) in the treatment of moderately to severely active Crohn's disease in patients who were naive to immunomodulator and biologic therapy, showed that a significantly greater proportion of patients receiving REMICADE achieved steroid-free remission and mucosal healing compared with patients receiving azathioprine.

16 Apr 2010

Survey reveals Gamunex as preferred IGIV therapy among neurologists

Talecris Biotherapeutics, Inc., today announced results of a new survey showing that Gamunex® (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) is the preferred immune globulin intravenous (IGIV) among neurologists who indicated a brand preference. In the survey, conducted online by Harris Interactive® on behalf of Talecris, neurologists selected Gamunex over four times more often than all other available liquid IGIV therapies, with a statistically significant margin (p<0.05).

13 Apr 2010

Spring storms present a worse scenario for asthma and allergy patients

While spring storms get comprehensive coverage during weather casts, a close look at local allergy indexes make the thunder and lightning seem downright puny.

13 Apr 2010

Nationwide Asthma Screening Program to find people at risk

The American College of Allergy, Asthma and Immunology will help adults and children to find out if they are at risk for asthma through its Nationwide Asthma Screening Program. More than 200 screenings will take place across the country this year. Locate one near you on the calendar of screenings available at AllergyAndAsthmaRelief.org.

12 Apr 2010

WTC FDNY Rescue Workers have not recovered normal lung function, yet

A study of nearly 13,000 rescue workers from the Fire Department of the City of New York (FDNY) shows that the significant proportion who suffered acute lung damage after exposure to World Trade Center (WTC) dust have not recovered normal lung function in the years since the September 11, 2001 terrorist attacks.

8 Apr 2010

Allergy flare-ups due to indoor allergens

Spring is here and allergy flare-ups are often attributed to the allergens outside your front door. However, did you know that the same allergens are found on surfaces inside 75 million homes across America? According to the Centers for Disease Control and Prevention (CDC), some of the most common indoor allergens include dust mites, mold and household pets.

8 Apr 2010

Health officials monitor cases of pandemic H1N1 flu in the Southeast

The continued spread of H1N1 influenza virus this spring is cause to pay heed to upper-respiratory maladies such as congestion, runny nose and cough, says David Kimberlin, M.D., a preeminent influenza specialist who co-directs the University of Alabama at Birmingham (UAB) Division of Pediatric Infectious Diseases.

6 Apr 2010

Passengers on Brisbane train may have been exposed to measles

A NSW man who was diagnosed with measles travelled in a train from the Brisbane International Airport to South Brisbane about 8am on Saturday.

2 Apr 2010

Rite Aid's fiscal 2010 fourth-quarter revenues down 3.6%

Rite Aid Corporation today reported financial results for the fourth quarter and fiscal year ended February 27, 2010.

31 Mar 2010

PhRMA report: 234 medicines in development for special health care needs of children

America's pharmaceutical research and biotechnology companies are developing 234 medicines for the special health care needs of children, according to a new report released today by the Pharmaceutical Research and Manufacturers of America.

31 Mar 2010

Community awareness can help fight tuberculosis

Pennsylvania Health Secretary Everette James today stressed the importance of increasing awareness of tuberculosis, or TB, and continuing efforts to control the infectious airborne disease that killed nearly 2 million people in 2008.

24 Mar 2010

Researchers create audio CDs to encourage physical activity among school students

The National Institutes of Health has awarded Albert Einstein College of Medicine of Yeshiva University $1.22 million to combat childhood obesity in the Bronx.

24 Mar 2010

EMA validates InterMune's pirfenidone MAA for IPF

InterMune, Inc. today announced that the company's Marketing Authorization Application (MAA), submitted on March 2 seeking approval of pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF) in adults, was validated by the European Medicines Agency (EMA). Validation of the MAA by the EMA indicates that the application is complete and that the review process will begin on March 24. The proposed trade name for pirfenidone in both the United States and Europe is Esbriet®.

23 Mar 2010